📊 VCEL Key Takeaways
Is Vericel Corp (VCEL) a Good Investment?
Vericel demonstrates exceptional financial health with a fortress balance sheet (0.04x Debt/Equity), strong liquidity, and positive free cash flow generation, but is hampered by stagnant revenue growth (0% YoY) and declining operational efficiency (4% operating margin despite 74.4% gross margin). The business is financially safe but operationally challenged in a sector requiring consistent innovation and growth.
Why Buy Vericel Corp Stock? VCEL Key Strengths
- Exceptional gross margin of 74.4% indicates strong product pricing power and competitive positioning
- Fortress balance sheet with minimal debt, $100.1M cash, and 5.03x current ratio providing financial security
- Positive free cash flow of $24.7M with 9% FCF margin and low capital intensity demonstrates cash generation capability
VCEL Stock Risks: Vericel Corp Investment Risks
- Revenue growth completely flat at 0% YoY in a growth-dependent biotech sector signals business stagnation
- Operating margin of only 4% despite high gross margins indicates excessive operating costs and operational inefficiency
- Poor capital returns with ROE of 4.7% and ROA of 3.4% show the balance sheet is not generating meaningful shareholder value
Key Metrics to Watch
- Revenue growth trajectory and pipeline success
- Operating margin expansion and cost structure efficiency
- Return on equity and capital efficiency improvements
Vericel Corp (VCEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.03x current ratio provides a solid financial cushion.
VCEL Profit Margin, ROE & Profitability Analysis
VCEL vs Healthcare Sector: How Vericel Corp Compares
How Vericel Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vericel Corp Stock Overvalued? VCEL Valuation Analysis 2026
Based on fundamental analysis, Vericel Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vericel Corp Balance Sheet: VCEL Debt, Cash & Liquidity
VCEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vericel Corp's revenue has grown significantly by 80% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
VCEL Revenue Growth, EPS Growth & YoY Performance
VCEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $57.9M | -$553.0K | $-0.02 |
| Q2 2025 | $52.7M | -$553.0K | $-0.01 |
| Q1 2025 | $51.3M | -$3.9M | $-0.08 |
| Q3 2024 | $45.6M | -$901.0K | $-0.02 |
| Q2 2024 | $45.9M | -$3.9M | $-0.10 |
| Q1 2024 | $41.0M | -$3.9M | $-0.08 |
| Q3 2023 | $38.3M | -$3.7M | $-0.08 |
| Q2 2023 | $36.8M | -$5.0M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vericel Corp Dividends, Buybacks & Capital Allocation
VCEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vericel Corp (CIK: 0000887359)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VCEL
What is the AI rating for VCEL?
Vericel Corp (VCEL) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VCEL's key strengths?
Claude: Exceptional gross margin of 74.4% indicates strong product pricing power and competitive positioning. Fortress balance sheet with minimal debt, $100.1M cash, and 5.03x current ratio providing financial security.
What are the risks of investing in VCEL?
Claude: Revenue growth completely flat at 0% YoY in a growth-dependent biotech sector signals business stagnation. Operating margin of only 4% despite high gross margins indicates excessive operating costs and operational inefficiency.
What is VCEL's revenue and growth?
Vericel Corp reported revenue of $276.3M.
Does VCEL pay dividends?
Vericel Corp does not currently pay dividends.
Where can I find VCEL SEC filings?
Official SEC filings for Vericel Corp (CIK: 0000887359) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VCEL's EPS?
Vericel Corp has a diluted EPS of $0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VCEL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vericel Corp has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VCEL stock overvalued or undervalued?
Valuation metrics for VCEL: ROE of 4.7% (sector avg: 15%), net margin of 6.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VCEL stock in 2026?
Our dual AI analysis gives Vericel Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VCEL's free cash flow?
Vericel Corp's operating cash flow is $51.9M, with capital expenditures of $27.2M. FCF margin is 9.0%.
How does VCEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.0% (avg: 12%), ROE 4.7% (avg: 15%), current ratio 5.03 (avg: 2).